BiotechTube

Secukinumab 150 milligram [Cosentyx]

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis, Ankylosing Spondylitis

Trial Timeline

Jan 15, 2019 → Feb 1, 2021

NCT ID
NCT03639740

About Secukinumab 150 milligram [Cosentyx]

Secukinumab 150 milligram [Cosentyx] is a approved stage product being developed by Novartis for Axial Spondyloarthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03639740. Target conditions include Axial Spondyloarthritis, Ankylosing Spondylitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03639740ApprovedUNKNOWN

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
Brodalumab + PlaceboKyowa KirinPhase 3
77
Ixekizumab + PlaceboEli LillyPhase 3
77
Ixekizumab + PlaceboEli LillyPhase 3
77
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
77
SHR-1314Jiangsu Hengrui MedicinePhase 1
33
UpadacitinibAbbViePre-clinical
23
AdalimumabAbbVieApproved
85
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
77
adalimumab + PlaceboAbbViePhase 3
77
TreatmentMerckPre-clinical
23
GolimumabMerckPhase 3
77
Tulisokibart + PlaceboMerckPhase 2
52
secukinumabNovartisPre-clinical
23
Secukinumab + PlaceboNovartisPhase 3
77
Secukinumab + Placebo + SecukinumabNovartisApproved
85
Secukinumab + Secukinumab and PlaceboNovartisPhase 3
77
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
77
Brodalumab 210 mg + PlaceboAmgenPhase 2
51
Etanercept 25mg + SulfasalazinePfizerPhase 2
51

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85